Hosted on MSN
Boston Scientific (BSX) expands urology portfolio with Valencia deal, analysts emphasize organic growth
Boston Scientific Corporation (NYSE:BSX) is included in our list of the best stocks to buy right now. A dose bottle of the medication is in the medical tech's hand On January 12, 2026, Boston ...
On January 12, 2026, Boston Scientific Corporation (NYSE:BSX) shared an expansion update, announcing a definitive agreement to acquire Valencia Technologies. With this move, the company expands its ...
Boston Scientific is recommended as a buy with a $109 target price, implying 14% upside, driven by robust demand and niche leadership. BSX outpaces market growth through focused M&A, strong execution ...
In the latest close session, Boston Scientific (BSX) was down 1.02% at $91.75. The stock's change was less than the S&P 500's daily gain of 0.21%. Elsewhere, the Dow saw an upswing of 1.35%, while the ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Boston Scientific has been ...
For me, buying a publicly traded stock is no different than buying an interest in a private business. In either case, I would only invest in a company that’s well-managed, with a valuable product line ...
Boston Scientific is one of those companies that most people never think about until they need it. Its products are not seen on drugstore shelves or marketed on television. Instead, they sit inside ...
Over the past several years, Boston Scientific BSX has pursued a series of acquisitions in support of its growth strategy, both strengthening its core businesses and expanding into high-growth ...
Hosted on MSN
Boston Scientific’s Financial Outlook: Key Risks and Challenges Highlighted in Latest Annual Report
Boston Scientific (BSX) has disclosed a new risk, in the Regulation category. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights ...
On Wednesday, Boston Scientific Corporation (NYSE:BSX) reported third-quarter 2025 revenues of $5.07 billion, beating the consensus estimate of $4.97 billion. The medical technology giant reported ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results